Copper Balance in Healthy Participants Administered ALXN1840
Study Identifier:
ALXN1840-HV-108
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
Date
Jul 2020 - Nov 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years
Requirements Information
Sex
Female & Male
Age
18 - 45 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
Date
Jul 2020 - Nov 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years years
Requirements Information
Protocol Summary
The study will assess the change from baseline in mean daily copper balance in healthy participants with repeat-dose administrations of ALXN1840 over 2 weeks.
Trial Locations
Location
Status
Location
Clinical Study Site
London, United Kingdom
Status
N/A